Literature DB >> 10828887

Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation.

R Bernardi1, D A Liebermann, B Hoffman.   

Abstract

Members of the cdc25 family are protein phosphatases that play pivotal roles in cell cycle progression. Cdc25A has been shown to be a critical regulator of the G1/S transition of mammalian cells and to be a myc-target gene with oncongenic properties. We investigated the regulation of cdc25A during terminal differentiation using myeloblastic leukemia M1 cells, that can be induced to undergo differentiation into macrophages by interleukin-6 (IL-6) treatment. In this report it is shown that cdc25A protein is degraded by the ubiquitin-proteasome machinery in both terminally differentiating and cycling cells. Cdc25A was found to have two major peaks of accumulation during cell cycle progression, one in G1 and the other in S/G2. Evidence was obtained that degradation of cdc25A by the ubiquitin-proteasome machinery in terminally differentiating myeloid cells is accelerated compared to cycling cells. Moreover, deregulated expression of c-myc in M1 cells, which had been previously shown to block terminal differentiation, was also found to block IL-6 induced degradation of cdc25A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828887     DOI: 10.1038/sj.onc.1203564

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest.

Authors:  Neil A Bhowmick; Mayshan Ghiassi; Mary Aakre; Kimberly Brown; Vikas Singh; Harold L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

2.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.

Authors:  Don X Nguyen; Thomas F Westbrook; Dennis J McCance
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.

Authors:  Kyung Bo Kim; Craig M Crews
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

5.  JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1.

Authors:  Mingli Yang; Song Wu; Jinghua Jia; W Stratford May
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

6.  Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability.

Authors:  Niels Mailand; Alexandre V Podtelejnikov; Anja Groth; Matthias Mann; Jiri Bartek; Jiri Lukas
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

Review 7.  Interlinking interleukin-7.

Authors:  Christina Kittipatarin; Annette R Khaled
Journal:  Cytokine       Date:  2007-09-04       Impact factor: 3.861

8.  Borna disease virus nucleoprotein interacts with the CDC2-cyclin B1 complex.

Authors:  Oliver Planz; Stephan Pleschka; Katja Oesterle; Friederike Berberich-Siebelt; Christina Ehrhardt; Lothar Stitz; Stephan Ludwig
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding.

Authors:  Mei-Shya Chen; Christine E Ryan; Helen Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

10.  Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.

Authors:  Y Honaker; H Piwnica-Worms
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.